Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
October 19, 2021
Earnings Call Speaker Segments
Nicholas Rolli
executiveGood day, everyone, and thanks for being here. We released a press statement earlier today with full details about how we performed in the third quarter of 2021. That release can be found at www.pmi.com. You'll find a glossary of terms at the back of today's webcast slides, which are up on our site — that includes how we define reduced risk products, or RRPs, along with adjustments. It also covers other calculations and reconciliations to the most directly comparable U.S. GAAP measures, plus extra heated tobacco unit market share data. Any mention of IQOS, our IQOS Heat Up Burn products, or smoke-free products should be understood as referring to our RRPs, unless we say otherwise. When we talk about growth rates on an organic basis, those reflect underlying results with no currency effects. After buying Fertin Pharma, Otitopic, and Vectura Group, PMI introduced the other category in the third quarter of 2021. Results for that other category get assessed apart from the geographical operating segments. Some of what we say today includes Forward-looking statements and projections of future results. I'd point you to the Forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or Forward-looking statements. Also, please take note of the additional Forward-looking and cautionary statements related to COVID-19. At this point, I'm happy to welcome A — Emmanuel Babeau, our Chief Financial Officer. Emmanuel.
Emmanuel Babeau
executiveThank you, Nick, and hi everybody — I'm glad you could be with us today, and I trust that each of you tuning in is keeping safe and well. Our company delivered another strong set of results in the third quarter of 2021, coming in ahead of our expectations and posting an all-time quarterly high for adjusted diluted EPS of $1.58. The biggest highlight was IQOS, which kept up its remarkable roll-out, driving +33% organic growth in Q3 RRP net revenue, while overall PMI was up +7.6%. HTU shipment volumes increased +24% compared with the prior-year period, hitting 23.5 billion units, with broad-based advances for both our volume and the category across key geographies. We managed that despite continued constraints on device supply stemming from the global semiconductor shortage, which dampened the pace of IQOS user growth. Turning to combustibles, further sequential share gains pushed total PMI shipment growth to 2.1% in Q3, and we continue to expect to meet our total cigarette and < > objectives for the year. We are still well placed to post a strong 2021 organic growth figure, with an expected currency tailwind contributing additional growth in the < >. We're also delighted to share outstanding early results for IQOS ILUMA in Japan, together with gathering momentum for IQOS VEEV in its first launch markets. In the quarter, we closed three milestone acquisitions as we put money into our business for the long term, bringing in products that go beyond tobacco and nicotine. Our smoke-free transformation is now also reflected in the way we fund the company, thanks to the launch of an industry-first business transformation linked financing framework. And we continue to put shareholder returns first through a 4.2% dividend increase along with ongoing share repurchases, which totaled roughly $170 million through October 15. Now for the headline numbers: Q3 net revenue grew +7.6% organically, or +9.1% in dollar terms. That reflects IQOS's continued momentum and the recovery of the < > business in many markets. We recorded healthy organic growth of plus 5.4% in net revenue per unit, driven by IQOS accounting for a larger share of our sales mix as well as pricing on both HTUs and combustibles. Our adjusted operating income margin declined by 10 basis points organically. That reflects the expected initially higher unit cost of IQOS ILUMA plus increased commercial spending partly related to its launch, which outweighed the continued favorable effect of IQOS's rising weight and profitability, pricing, and productivity savings. Our resulting adjusted diluted EPS of $1.58 equates to +8.5% organic growth and +11.3% in dollar terms — a very solid performance. Now turning to year-to-date results, adjusted net revenues were up by almost +11% in dollar terms and by +7.3% organically. That reflects IQOS's consistent growth, where progress throughout the pandemic has been outstanding; we delivered strong organic growth of almost +6% in net revenue per unit, again reflecting our changing business mix and pricing, with combustible pricing at just over 3%, or roughly 5% excluding Indonesia. So far this year, our adjusted operating income margin has climbed 280 basis points on an organic basis — an exceptionally solid outcome, driven by net revenue growth, IQOS performance, and pricing, plus operating leverage and productivity savings. Organically, adjusted diluted EPS increased 15.8%, and in dollar terms it was up 20.4%; obviously, those are very strong results too. That brings me to the 2021 guidance. On net revenues, we're raising our organic growth projection to between plus 6.5% and plus 7%, the upper half of the earlier range, and we're restating our confident view for organic OI margin expansion of about 200 basis points; we're also confirming that currency-neutral adjusted diluted EPS growth should come in at the top end of our previous range, reflecting growth of +13% to +14%, or +16% to +17% in dollar terms. That translates to an adjusted diluted EPS range of $6.01 to $6.06, which incorporates an estimated sub variable currency impact of $0.17 at prevailing rates. Following up on our most recent comments, with device supplies remaining tight, we now project our HTU shipment volume at approximately 95 billion units, as we're prioritizing devices for user retention. With HTUs still expanding and the need to maintain inventory duration at its current level, we continue to expect full-year shipments slightly above IMS volumes; this guidance doesn't include any material impact from share repurchases or acquisitions. Share repurchases through October 15 come to roughly $117 million, following some limitation during Q3 due to blackout restrictions. On other assumptions, we're factoring in only a limited Q4 recovery in duty-free after a modest Q3 improvement, with intercontinental and Asian travel remaining very subdued. We still assume fully accomplishable pricing of +2 to +3%, with a softer expected Q4 reflecting continued pandemic-related challenges in certain markets, notably in South and Southeast Asia, as well as tough comparison in Germany and Australia. Finally, in 2021, we still expect around $11 billion of operating cash flow at prevailing exchange rates, subject to year-end working capital requirements. We're also updating our expectation for full-year capital expenditures to around $0.6 billion, reflecting the latest launch plans and pandemic related planning factors. Before discussing depth, I'm pleased to report some recent positive regulatory development further to the shares in previous quarters. For instance, Switzerland adopted a new federal law on tobacco products and in cigarettes defining a dedicated product category and differentiated as warnings. In New Zealand, the government has now published new regulation for smoke-free products, which allow branded packaging to be reintroduced with a specific text as warning; in Egypt, earlier this year, smoke-free products were clearly differentiated from combustible cigarettes in both fiscal and regulatory treatment. There is a growing body of scientific and real-world evidence of the substantial risk reduction potential of non-combustible alternatives compared with smoking. While fluctuations across different markets are to be expected, we continue to support regulatory and fiscal frameworks that recognize this critical reduction opportunity. Let's go back over the figures. During the third quarter, our total shipment volume increased 2.1%, while on a year-to-date basis it was higher by 1.5%. That reflects sustained strong growth in HTU, which was up 24%, driven by the EU region, Japan, Russia, and Ukraine, together with promising momentum from Middle Eastern markets we have recently entered. In Q3, HTU shipments landed at approximately 1 billion units below IMS volume, largely owing to timing tied to the August ILUMA launch and Japan's tax-related price increase in October. We expect this situation to reverse in Q4. Cigarette volumes for Q3 fell 0.4%, consistent with the ongoing sequential rebound in both overall industry volume and our market share. Given IQOS's outstanding results, heated tobacco units accounted for 13% of our total shipment volume year-to-date, against 11% for the whole of 2020, 8% in 2019, and 5% in 2018. Our sales mix is changing fast, which keeps us on course to reach our ambition of becoming a majority smoke-free Company by 2025. Year-to-date, smoke-free products represented close to 30% of our adjusted net revenue, versus 23% during the equivalent period of 2020, and IQOS devices accounted for over 6% of the $6.7 billion in RP net revenue. That accelerated in Q3, owing to the IQOS into my launch, which more than compensated for the effect of supply constraints on other acquisitions. Separately, share repurchases through October 15 total approximately $170 million.
Emmanuel Babeau
executiveThrough the year so far, organic net revenues are up 7.3%, while shipment volumes have risen 1.5%, and together those two numbers show the twin forces driving our top line. The first is pricing, which we've applied to combustible products and, in certain markets, to HTUs. The second is a growing mix of HTUs in our business, which bring in more net revenue per unit, and that keeps adding substantial growth while turning into an increasingly powerful force as our transformation accelerates. Let me now take you through what's behind our margin improvements this year, starting with gross margin, which is up 240 basis points on an organic basis. The gain was smaller in Q3, because ILUMA devices shipped to Japan for that launch, but the many favorable elements discussed in prior quarters are still very much with us. Significant efforts around manufacturing and supply chain efficiency are bearing fruit as well, generating about $450 million in gross productivity savings. On top of that, we saw strong SG&A gains, with adjusted marketing, administration, and research costs for the year to date down 40 basis points as a proportion of adjusted net revenue on an organic basis. That reflects our ongoing digitalization and simplification of how we operate, including the IQOS commercial engine and more efficient ways of working, partly offset by stepped-up commercial investment in Q3. With SG&A savings above $200 million before inflation and reinvestment, we've now achieved over $650 million in total growth efficiencies year-to-date. That's meaningful progress against the combined $2 billion target for 2021, 2023. Moving to market share, sequential gains across both our IQOS and combustible portfolios leave us carrying good momentum into Q4 and the year ahead, despite a roughly 3-point year-over-year drag in Q3 that came from market mix, alongside an approximate 0.3-point year-over-year drag in Q3 from market mix. Importantly, we expect further HTU gains in the fourth quarter, with record shares across major IQOS geographies. On combustibles, the improved total market volume picture shows clear recovery in Indonesia, Turkey, and Mexico, plus nearly flat Q3 industry volumes in the EU region. Our combustible category share has rebounded sharply on a sequential basis, moving us closer to the goal of stable share as our portfolio initiatives pay off and pandemic-related restrictions loosen across many markets. In South and Southeast Asia, new COVID-linked measures have somewhat held back the recovery. Even so, industry volume has still improved sequentially in Indonesia and the Philippines, where the year-over-year comparison faces a tough prior-year base. Our share in that region improved sequentially, though by less than expected, largely due to pandemic-related developments in the Philippines. Let's turn now to the device supply constraints stemming from the global semiconductor shortage. As we noted in September, with demand still rising, this has already affected the availability and assortment of IQOS devices in certain markets during Q3, which limited our ability to operate at full commercial and competitive strength and to meet consumer demand. Device shipments outside Japan were held to a 7% year-over-year increase, well below net sales growth. The net effect was that user growth decelerated in the quarter by roughly several 100,000, with Russia the most obvious example, since the restriction put IQOS on the 4 plus device, something we had flagged in our recent communication. Market mix also created an approximately 0.3 point year-over-year headwind in Q3. As matters stand, clarity on semiconductor supply remains unreliable, so we assume the tight supply situation will persist through the first half of 2022. Our ongoing strategy will be to carefully prioritize replacement devices for existing users, and then device sales for acquisition. IQOS ILUMA's strong launch in Japan demonstrated it would contribute meaningfully to both acquisition and retention. That said, at the outset it triggers considerable upgrades within the sizable installed IQOS base, many of whom truly had no need to replace their devices. In a normal supply environment, that is precisely the consumer behavior you want, yet amid a shortage it compounds the pressure. We therefore now assume that additional major launches would take place only in the second half of next year. Amid this changing backdrop, we have maintained substantial commercial investment in key areas. That includes portfolio expansion and product introductions such as IQOS ILUMA in Japan and IQOS VEEV, the smoke-free category, understanding and awareness initiatives, as well as a range of commercial development projects. Including investment already made in Q3, we anticipate approximately $300 million in extra H2 spending versus the first half. All told, this is a temporary phenomenon, and because demand remains strong, we expect user growth to resume once shortages ease. We possess a pipeline of exciting innovation across devices and consumables, including but not limited to ILUMA, together with several planned new market entries. Nevertheless, under a near-term shortage scenario, the transitory supply effect on user growth could cause 2022 organic growth to fall below the 2021, 2023 targeted average rate for net revenues, OI margin expansion, and adjusted diluted EPS. Nevertheless, with a solid 2021 as our foundation and a strong rebound once supply constraints lift, we reaffirm our confidence in the 2021 to 2023 growth targets. Turning to IQOS performance, we estimate the number of IQOS users at 20.4 million as of September the 30th. Excluding the effect of international sanctions in Belarus, that equals growth of approximately 0.4 million users in the quarter, with the pace held back by device supply tightness and the time required to fine-tune our commercial programs. As the ILUMA launch in Japan showed once more, the underlying momentum behind the IQOS brand is still strong. Once we adjust our program and assortment, we look for Q4 user growth to come in a few 100,000 higher than what we saw in Q3. The lower user growth in the second half ought, therefore, to line up broadly with the potential 2 to 3 billion HTU impact we flagged in recent communications. We figure that 73% of all users — that's 14.9 million adult smokers — have made the switch to IQOS and stopped smoking, while the remainder are somewhere along the conversion path. Yet again, user expansion tracks acquisition throughout the main IQOS markets, even with the device shortage. Turning to the EU, in Q3 the combined share reached 5.3% of total cigarette and HTU industry volume, an increase of 1.4 points versus the same period last year. Market mix created a drag of roughly 0.3 points year over year in Q3. As we mentioned last quarter, we expect HTU sequential share to remain roughly level, given that seasonality and pandemic-related fluctuations in the combustible market come into play. The underlying IMS growth trends continue to be excellent. As in the prior year, we expect a strong Q4 for both volume and market share; this very solid performance includes robust gains across the region, with Italy, Germany, and Poland emerging as leading contributors. Momentum continued in Russia, where our Q3 HTU share climbed 1.1 point to 6.9%, and while that sits under Q2 — mainly owing to combustible market seasonality — we expect further sequential IMS growth that should deliver a sizable quarterly share increase in Q4, in line with last year. In Russia we encountered the tightest limits on lower-priced devices and the commercial programs tied to them; and we've seen a bit more consumer trial of a rival's discounted disposable e-vapor product. All the same, we continue to observe substantial interest in the category, and given our existing price tier portfolio along with forthcoming innovation that supports our clear category leadership, we see ample opportunity for ongoing strong growth ahead.
Emmanuel Babeau
executiveEastern Europe is also showing growth in H2, thanks to contributions from Ukraine, Kazakstan, and southeast Europe. This slide shows the overall positive regional growth trend in adjusted IMS, although it's somewhat dampened sequentially by the halt of shipments to Belarus due to International sanction and a timing factor in Kazakhstan. In Japan, our HTU brands' adjusted total tobacco share increased by plus 2 points versus the prior-year quarter, reaching 20.8%, and adjusted IMS grew sequentially to hit a record high of 8.2 billion units, which reflects the strength of our portfolio and the launch of IQOS ILUMA. On a sequential basis, our adjusted share decreased 0.2 point. That reflects swings in the overall market before the October 1 excise hike, plus the usual seasonal patterns. A pantry-loading effect from consumers might not show up until our Q4 IMS, but we still anticipate solid underlying volume growth and a decent step-up in share from one quarter to the next. The heated tobacco category as a whole keeps expanding — it accounted for nearly 30% of the adjusted total Japanese tobacco market in Q3 — and IQOS held a high portion of that segment while taking most of the category's growth. Beyond the strong performance in markets where we already operate, we keep pushing our smoke-free product into new geographies, with the goal of being present in one additional market by 2025. In the quarter, we brought IQOS to Egypt—marking its debut on the African continent—and in Europe and Cairo, we achieved an off-take exit share of 2%. Norway and Iceland are now included as well; our recent acquisition of < > provides us with a presence in the < > and nicotine pouch category. As a result, the < > snooze brings the total count of markets where PMI smoke-free products can be purchased to 70, with 28 of those being low and middle-income markets—a figure we're presenting as a stronger gauge of making smoke-free products accessible to adult smokers in emerging countries. Once again, delays in this market expansion program are possible during the first half of 2022. Because we lead in smoke-free products and operate worldwide, I want to take a moment to discuss how solid our intellectual property is. For every one of our smoke-free offerings, we hold robust patents, and as the obvious front-runner in innovation within the tobacco sector these past several years, we've put billions of dollars into that effort. This is true even though your competitor—someone trailing us in R&D and innovation—has tried to interfere with our business by going to court. We've been—you need us to win when protecting our products from IP disputes in each of the 11 decisions handed down beyond the U.S., which includes the UK high court and the European Patent Office. The U.S.A.—the U.S. The ITC is a federal body that handles imports, among its other responsibilities, and it's tasked with safeguarding American companies' intellectual property. We'd also point out that both of the pathways I referenced in the ITC's final determination came about only after IQOS had already hit the market. The FDA — the agency Congress gave exclusive authority over tobacco product oversight — has determined that IQOS furthers the objective of protecting public health and is expected to bring benefits for the well-being of the whole population. While this presidential review is underway, we're hopeful that the U.S. Trade Representative will take into account what's at stake for Americans who use IQOS today, as well as the much larger group who would be locked out. Should the ITC's decision stand, and given that the monetary effect at this point is immaterial because the U.S. IQOS rollout is still at an early stage, the unfortunate result would be that American buyers could not obtain IQOS for some period. In the meantime, our backup strategies are in motion, and they involve producing domestically. Certain claims tied to the patents at issue are being examined by the U.S. patent office, with a first decision anticipated during 2022, and that could be appealed. Although the ITC's ruling might bring short-term interruption to IQOS availability in America, we still perceive a substantial opportunity for IQOS across the United States in the years ahead. August marked a landmark moment for the worldwide IQOS innovation narrative, as we introduced two ILUMA devices plus a lineup of < > HTUs in Japan. Leveraging what we achieved with IQOS 3 Dual, we expect this straightforward, intuitive device—thanks to SmartCore internal induction heating technology—to enable simpler switching and greater conversion among < > edge smokers. With the nationwide rollout beginning in early September, early outcomes were remarkable: device sales ran well above every comparable prior launch at the same point, even with some constraints on device supply, and the share of new users climbed to 18%. < > purchases are rising swiftly, finishing the quarter above 10% of total PMI HTU of tech volume. Consumer response has been strongly favorable too, with meetings showing gains in the net < >. Given that success, we intend to enter our second market, Switzerland, next month, and we look forward to further major launches during 2022 as conditions permit. We keep commercializing IQOS VEEV, making solid headway in the first set of markets, where we began within our own channels using a limited selection of taste variants and nicotine levels. IQOS VEEV is a premium offering that delivers a superior experience; and IQOS's commercial infrastructure lets it be deployed efficiently and at scale via a tailored route-to-market approach. As we begin broadening distribution and the consumable lineup, we observe signs of rising uptake and clearly positive consumer feedback versus competing products. We see encouraging early success in Italy, where VEEV hit an estimated 7% national exit volume of tech share of crude system product — system put, sorry, even though it is not yet sold nationwide. And in the Czech Republic, with an estimated 8% national volume of tech exit share. Additionally, we began operations in Croatia during the third quarter, entered Canada in October, and intend to start in Ukraine prior to the close of the year; furthermore, we keep getting ready to submit a PMTA application to the U.S. FDA during the latter half of 2022. Now shifting to our approach for expanding into fresh commercial domains outside of tobacco and nicotine, an approach centered on using and enhancing what we already do well in health care and wellness; we identify considerable potential in a nearby sector through our two concentrated channels of self-care wellness, which include botanicals and inhaled therapeutics, anticipated to represent a market opportunity worth roughly $65 billion by 2025. Buying Fertin Pharma, Otitopic, and Vectura let us speed up the growth of our development resources, bringing more than 250 scientists, facilities, technology, and know-how in cutting-edge enameled and oral product formulation, all while we keep expanding CDMO operations. As this slide illustrates, that creates numerous strongly synergistic possibilities and fresh priority zones; this deal will completely capitalize on PMI's established strengths such as science, product innovation, and clinical know-how tied to innovation. We anticipate sharing further updates with you later regarding our initiatives and advancement in these thrilling new fields. Shifting to sustainability and our ESG goals, we keep achieving solid headway across our < > by pushing forward with our transformation and tackling our most significant effects on society.
Emmanuel Babeau
executiveWe're expanding how people can get our smoke-free products by making them more available to adult smokers globally, rolling out new launches across a widening set of markets and smoke-free segments. On top of that, our recent acquisition strengthens our human, intellectual, and social capital, brings added smoke-free capabilities, and establishes the groundwork for a solid business in areas outside tobacco and nicotine, as we work to create commercially successful products aimed at delivering a net positive impact on society. I take pride in pointing to the recent release of our business transformation linked financing framework, along with the ensuing refinancing of our revolving credit facility. That framework, which adheres to ICMA principles and has received a second party opinion from S&P, ties our financing to < > targets within our transformation. Finally, we are still on course to reach carbon neutrality in our direct operations by 2025, which is five-years sooner than our 2030 goal. Also, as the United Nations Climate Change Conference draws near, we intend to release a strong low carbon transition plan together with a white paper on climate justice, underscoring how environmental and social matters are connected. All in all, we are set for outstanding top and bottom-line growth in 2021, backed by solid underlying momentum for IQOS and healthy cash generation. We're putting money into widening our smoke-free product portfolio and extending our geographic footprint. That matters greatly as we aim to speed up the count of adult smokers switching to better alternatives, amplifying the beneficial effect on society. Beyond that, we're funding tomorrow's capabilities, as shown by our three recently announced acquisitions, which deliver a comprehensive development platform in safe care wellness and in health therapeutic, while reinforcing our standing in modern oral nicotine. We boosted cash returns to shareholders during Q3 via a larger dividend and our share repurchase program, consistent with our aim of providing sustainable value and returns to investors as we keep progressing toward becoming a majority smoke-free Company. Looking at 2022, we have a pipeline of exciting innovation spanning both devices and consumable. And we anticipate IQOS user growth will pick up speed again once device shortages ease; we still foresee a bright future for our business and stay confident in our 2021 to 2023 organic growth targets. Many thanks, and I'm now glad to take your questions.
Gaurav Jain
analystHello, and good morning. I appreciate you taking my questions.
Emmanuel Babeau
executiveEmmanuel Babeau:
Gaurav Jain
analyst< >. Let me start with a question about the 2022 unit figures. You mentioned growth would come in below the 2021 to 2023 range you provided, and the reason is problems with device supply. If device supply is smaller and your IQOS acquisition is smaller, doesn't that also mean your commercial investments are smaller, which should help your EPS? Or is that the wrong way to look at it?
Emmanuel Babeau
executiveThank you, Guarav, for asking. To begin, I want to say again that this represents one scenario — the idea that these constraints will remain with us during H1 next year — and it isn't the only scenario, since a more favorable one exists. And right now, honestly, the situation moves fast and is extremely fluid. So we don't know, but I believe it mattered a great deal to communicate the possibility that the availability pressure we're experiencing in H2 2021 will still be felt during H1 2022. That's the scenario you're asking about, and under it, following this six-month stretch in the second half of 2021, we'd face another six-month stretch with diminished acquisition, which reflects the underlying potential observed in H1. In that case, without question, spending would be affected by how many launches or commercial activities are taking place — that part is very clear. Yet at the same time, as we've stated plainly today, we hold complete confidence in IQOS's very strong potential. And we believe that potential has stayed completely untouched by current events. So once the shortage lets up, there will be a very good acceleration. Beyond that, we'll simultaneously bring very exciting innovation. You know ILUMA, and there's more in the pipeline. So even when availability is somewhat limited, we'll ensure we continue building awareness, continue building the category, and also the IQOS franchise. So not every cost will disappear, because we're going to — I mean, we're here to achieve success. As you know, over the long run, and not just handling 6 months. So yes, under this scenario — again, it's one scenario among others — there would be a reduction in investment. But as Q3 shows, we keep investing even when there's some limitation, because we're building that long-term success, which is extremely clear in the outlook we have.
Gaurav Jain
analystThanks. Then one more thing about what you're doing in America—there seem to be a lot of conflicting forces at play, since you've got that partnership with Altria for IQOS, yet you just came out on the losing end against VAT. There's also a chance you'll need to make your devices here in the country. On top of that, you intend to submit a PMTA for IQOS VEEV at some point in the coming year, which means that might become another new offering for American consumers. And you bought Fertin too, which gives you the ability to maybe introduce a modern oral product stateside should you put in a PMTA for it; so what's the right way to view this, given that in certain areas you'll be working alongside Altria while in others you might end up as its rival; how do all these pieces come together?
Emmanuel Babeau
executiveThanks, Guarav, for asking. Let me make this clear once more. Our commercial tie-up is with Altria, and both sides have tobacco products, so there's no ambiguity there. We'll wait and see how this ITC matter ultimately turns out. I won't speculate on where it lands; right now we're in the presidential review period. Honestly, we believe this will prove pivotal for the FDA's tobacco reduction goal. In our view, the administration now has a wonderful chance to demonstrate how vital this tobacco harm reduction approach is. That would involve safeguarding IQOS, the sole < > inhaled nicotine item currently enjoying < > within America. So we continue to hold hope that a favorable result will come our way following the presidential decision. Should that not be how it ends, naturally we'll keep collaborating with Altria. Things would get pushed back somewhat; we'll come up with a way around the ITC ruling. We've been pointing out that moving to local manufacturing is a possibility. And, as I believe I've mentioned in my remarks, our conviction remains firm regarding IQOS's enormous potential in America. That covers one point. Then there's the separate Altria category where we do indeed have aspirations, and as you noted, we plan to submit a PMTA for VEEV. At some stage we might also look at bringing out a modern oral product. Regarding that, every possibility remains on the table, since no commercial deal exists at present. In time we'll determine how we wish to proceed and what structure or partnership to use; however nothing has been settled as of now.
Gaurav Jain
analystThanks a lot, Emmanuel.
Emmanuel Babeau
executiveThank you, Guarav.
Bonnie Herzog
analystThank you. Hi, Emmanuel.
Emmanuel Babeau
executiveHello, Bonnie.
Bonnie Herzog
analystThere were a few points I wanted to raise regarding IQOS performance in the quarter. First off, any sense of how much stronger device sales could have been this quarter had supply not been constrained? Said differently, I'd like to hear how strong orders might be for new invites — devices, especially ILUMA. And maybe you could share the backlog's size. On that same note, I'm trying to understand what gives you confidence these issues will loosen up by the second half, plus what the situation looks like should these shortages drag on further. Finally on this topic, are there any backup plans under consideration, or approaches to lessen your dependence on semiconductor vendors going forward?
Emmanuel Babeau
executiveThanks, Bonnie. Taking your first question on IQOS device sales potential in Q3 without the constraint. We see we lost several 100,000 in device sales; that's obviously very, very material, and we've said that outside Japan — and we really must look outside Japan, since Japan was a special case with the ILUMA launch. So outside Japan, devices rose 7%, which is, naturally, far, far below the underlying growth of our markets. We're still expanding at close to 25% even in Q3; so I think that offers a sense of the kind of GAAP we may have encountered this quarter; we think, as I mentioned, that in Q4, since we now have a better grip, so to speak, on things, we've been handling the reassortment, reallotment; we understand better which commercial actions deliver the best possible return. We have a very clear view on how we're going to prioritize; so we think that we're growing even with the severe restriction on devices, I can't say whether that would be precisely the same level, but let's assume that, the same level as Q3, we think that in terms of user growth, we could do better than in Q3. And we mentioned a few 100 thousand better user growth acquisition. So all together, that means that if you accept that the underlying growth rate was between 4.5 to 5 million user a year that we're seeing in each one, we're going to miss anywhere between 1 to 1.5 million user growth in H2 altogether. So that lines up perfectly. This was already present back in September—right at the start of the month—and it matches the 2 to 3 billion figure we referenced then. Hopefully this gives you a clearer picture of how the device shortage is hitting us. You should really be seeing it firsthand. We're grinding away—truthfully, around the clock—to bring this shortage under control. We're pulling out every tool we have. So of course, we're in very active talks with our suppliers, exploring every possible option. Planning is where we're focusing most of our optimization efforts, and naturally that gets rather intricate, since the shortages touch multiple kinds of IC, and those don't each fall under an identical reference within our range. We're addressing that as well; we're also looking at how the situation varies across individual markets, and we've completed a few smaller acquisitions, and there's potential for us to see even stronger results there. So honestly, we're using every tool at our disposal to keep the impact minimized. At this moment, what we're hearing is that additional capacity should become available in the first half of next year. My own inclination is to think there's a kind of common understanding that the second half of next year should appear much better when it comes to constraints — perhaps even fully back to normal. That's the assumption we're operating under currently; however, I have to admit circumstances have changed rapidly, at a fast clip. And as I said, maybe things will improve earlier, because something could change in overall economic demand within the next 6 months. So an even stronger H1 could be on the table. That's one possibility. Does that suggest another scenario, where H2 becomes a larger uncertainty? Well, maybe. That's what we're hearing when we talk with our partners and suppliers so far. But I have to admit, at this point nothing is fully resolved. On an underlying basis, growth was running between 4.5 million and 5 million users a year.
Bonnie Herzog
analystAll right. That's really useful. If I could, I'd like to try and fit in one more short question. During this stretch when IQOS device sales are slower and new user acquisition is slower, what should we expect for your overall volume growth? So can we safely assume that your combustible cigarette volume will be higher while IQOS device sales are slower, and basically strong enough to more than make up for it? And with that in mind, how should we think about how this mix affects your margins over the next few quarters? Thanks.
Emmanuel Babeau
executiveSorry, the connection on your end wasn't very clear, but you were asking how we should expect the effect on user acquisition versus volumes, right?
Bonnie Herzog
analystApologies if that wasn't audible — my question is really about mix, Emmanuel, since my thinking is that while IQOS device sales are slower during this stretch, combustible cigarette volume might run higher.
Emmanuel Babeau
executiveYes.
Bonnie Herzog
analyst< > believing that shift in product combination could affect profit margins.
Emmanuel Babeau
executiveWell, we remain focused on achieving strong expansion for IQOS, and < > is a fantastic segment overall. Naturally, being the EPS frontrunner in that segment, we expect that momentum to carry on through upcoming quarters. As you're also aware, that brings along an excellent revenue-per-stick composition, and it remains clearly apparent in our Q3 figures. We additionally pointed out that this was favorable regarding gross margin rate for the consumables division, the IQOS operation. So perhaps should expansion slow somewhat due to circumstances, the beneficial mix will keep developing; it already has, though more slowly. Yet it will stay solidly favorable. Beyond that, naturally, the issue becomes, alright, how much will we allocate toward SG&A under these conditions. Thus it's hard to claim this will inevitably translate into a detrimental effect on margin. We're discussing an extremely strong catalyst for our financial results. And once more, even if the growth rate declines somewhat, it will remain considerably above any movement on < >. Plus it will keep generating a favorable effect on the mix.
Bonnie Herzog
analystOkay, thanks a lot once more.
Emmanuel Babeau
executiveThanks, Bonnie.
Pamela Kaufman
analystHello there, and good morning. I'd like to ask something that builds on what was discussed earlier.
Emmanuel Babeau
executiveMorning to you.
Pamela Kaufman
analystMorning. I'd like to ask something further regarding how we see things shaping up for the coming year, plus the situations that would put the risks underneath your midterm goal. From what I'm hearing, you expect supply to be softer during 1H and then get better in the back half. Under that situation, would your results end up beneath the side and 9% revenue and earnings growth target, or would supply conditions have to deteriorate beyond what you're assuming?
Emmanuel Babeau
executiveNaturally, with such a situation, there's no limit to how far we can speculate. We must acknowledge that a weakening of user growth has already shown up in Q3. As we've stated, versus — although we look for Q4 to improve compared with Q3, it will remain under the underlying trend; and so, in the situation we're laying out, we're saying that should shortages persist through H1 of next year, that's the point where this pressure on growth hits us. So for me to speak about just one situation is hard. Yet < >, it's the buildup of everything that's occurred during H2 of this year, 2021, together with what might occur as next year begins, meaning H1 2022, that could bring about a lowering of the potential growth rate in the coming year. That would be temporary, I'll say again, and once a rebound comes, the < > will arrive, but that mixture is what would set off something that might land under our average growth targets.
Pamela Kaufman
analystThanks. That's useful. Now I'd like to ask about the ITC ruling. Could you say more about what you'd do as a fallback to get IQOS into the U.S. market? When might U.S. manufacturing of IQOS happen? And to be clear, does that decision extend to ILUMA technology as well? When it comes to launching ILUMA in the U.S., could its PMTA be linked to IQOS's in order to speed up U.S. entry?
Emmanuel Babeau
executiveAs for the ITC fallback, should the presidential review ultimately turn out unfavorably — though before I respond, let me say again that we remain hopeful it will conclude in our favor, for the reason I gave earlier. Regrettably, I can't say more, but clearly that forms part of what we outlined, namely that local production could serve as one component, though I won't go into further detail about how that might work or how we'd reach that point; on the ILUMA PMTA — a PMTA, honestly, we'll have to talk with the FDA about the process, and the entire process would be handled by the FDA; and right now, I can't give you an answer; so we will definitely need — request a PMTA for ILUMA at some point, but I'm not in a position today to discuss timing.
Pamela Kaufman
analystOkay. Understood. Thank you.
Emmanuel Babeau
executiveThank you Pam.
Vivien Azer
analystHi, thank you. Good morning.
Emmanuel Babeau
executiveGood morning, Vivien.
Vivien Azer
analystSorry to keep going back to the ITC matter, but I have a question about that as well. You mentioned your history of winning when it comes to fighting litigation outside the US. Two things, if you don't mind. First, are there any IP lawsuits still ongoing in other countries right now? If there are, could you say where they are? And second, could you confirm whether the cases you've won involved the very same claims the ITC looked at? Thanks.
Emmanuel Babeau
executiveWell, several cases are still open, and I won't go into detail about them. Some of them aren't public. Especially in Europe, I'd like to say again that up to now in Europe, we've had 11 cases, whether at trial or on appeal, and we've won all of them; so I believe that says a great deal about how strong our position has been; and yes, a few of the patents the ITC relied on when it decided to take up the review, which were later examined by various European courts. And that would be the UK court; and they already have the < > and it's the UK court that has invalidated two patent families that were part of the original ITC decision. And the European Patent Office has already assessed one of those patent families, so even on the basic question of the patent's merit and its validity, we've had success in Europe.
Vivien Azer
analystThat's useful, thanks. My next question concerns combustible cigarettes. The forecast is improving slightly, and you've restated your pricing approach. From what I remember, when the year got underway, there seemed to be some hesitancy regarding pricing given COVID-related uncertainty and so on. How do you see the consumer? I realize that's a wide-ranging question, since you're present in many markets. Still, if you were somewhat conservative or careful about pricing at the start of the year, how do you feel now about your capacity to raise prices? Thanks.
Emmanuel Babeau
executiveWell, you'll need to let me have the rest of this year's weeks before I can say more about the coming year. In my view, what the environment will look like remains rather unclear. One could imagine that inflation, which is plainly speeding up across numerous countries, might perhaps produce a worldwide backdrop superior to our original assumptions, yet it's still early; therefore I cannot offer a view at this point, so I'll stay cautious, a stance that was formed, as you likely recall, in the wake of COVID and the fact that many economies have been hit hard. So we observed that this probably didn't set up a strong scenario for raising prices; however, I must acknowledge I don't know what effect will come from what appears to be a broad rise in inflation; and perhaps that will bring about a more advantageous set of circumstances, but please be patient with us, since it's still a few months until we can see this more clearly.
Vivien Azer
analystUnderstood. Thank you very much.
Emmanuel Babeau
executiveThanks, Vivien.
Chris Growe
analystThank you. Good morning.
Emmanuel Babeau
executiveHi Chris.
Chris Growe
analystI wanted to ask something. Hello, Emmanuel, and thanks. I have a brief additional question regarding the supply shortage. I apologize for returning to this topic, yet I did pick up on some impact concerning the 2.4 device. As I understand it, that is constraining ILUMA's rollout in certain markets. Does this chip shortage apply across your entire lineup, including the 3.0 and duo? I just want clarity on whether those are impacted by the chip shortage as well.
Emmanuel Babeau
executiveChris, answering that would require laying out in considerable depth the way we set priorities across our portfolio, and my inclination is not to go there, since this is, naturally, rather strategic for us. One thing that is entirely evident is that we have a single North Star, so to speak: first, safeguard the IQOS users we already have and guarantee a device is on hand whenever they wish to replace it; and second, we aim to maximize every commercial initiative so that the return is greatest on each new device we sell, while preventing, to the largest extent possible, the sale of a device that the consumer afterward uses at a very low percentage. And for us, certainly, shifting toward and capturing the advantage of advancing the blade technology, and prioritizing a move to IQOS 3 over IQOS 2.4+, was among the decisions we chose to take. That is why we face somewhat greater limitation, compounded by the fact that component problems also placed additional pressure on 2.4, though clearly at moments like this, when many considerations are in play, you are juggling constraints alongside a long-term strategic vision. That is precisely what we are doing.
Chris Growe
analystThanks for that context; and I have a separate question regarding a few of your beyond nicotine and tobacco acquisitions, Otitopic and Vectura, specifically respiratory drug companies. I just had a fairly straightforward, high-level question. Are additional pieces needed to complete that vision you hold for respiratory drugs? And just to grasp what stage we're at with respect to your acquisitions, to understand whether you need to do more here in the short-term, whether this is a solid base from which you can build this element of your beyond nicotine sales.
Emmanuel Babeau
executiveSo globally, we believe we have established, if you will, excellent platforms for beyond nicotine, and particularly when it comes to R&D. And I think there is a great deal we can already accomplish with this acquisition. Now, does that mean that going forward, we might consider another < > acquisition that would deliver additional capacity we perhaps lack here, but I think at present, we're going to concentrate on ensuring that we integrate this acquisition and we maximize the synergy. In the interview as I mentioned, regarding R&D, which were truly two major objectives to combine strengths on R&D. And we optimize by placing — you know, all our skills, talent together, we optimize what we can already do in therapeutic, but I could also make that remark for 13 and self — care wellness.
Chris Growe
analystAnd I just want to confirm — none of these deals will pull you off course from that other objective you have of buying back your stock, right? That's really the key point I was focused on, mainly to get a handle on what capital commitments lie ahead over your < >.
Emmanuel Babeau
executiveNot at all. No, definitely not. There's been zero change to our repurchase plan. None whatsoever.
Chris Growe
analystThat's wonderful. Thanks a lot. Have a nice day.
Emmanuel Babeau
executiveThanks.
Callum Elliott
analystThank you for asking. Emmanuel, if I could just jump in — would you mind addressing how taxes apply to IQOS in Germany? Of course, we all know the political picture there remains somewhat unclear. Still, it looks as though the tax revisions on the table could significantly drag down price mix and profitability in the coming year, so I'd appreciate it if you could give us a sense of how large that effect might be. Then, zooming out a bit, is there a growing danger that similarly steep IQOS tax hikes spread to additional markets?
Emmanuel Babeau
executiveRegarding Germany, what I can definitely say again is that we have somewhat conflicting reactions to what Germany decided. On one hand, it makes us quite glad that a nation as significant as Germany is acknowledging that these products are improved and deserve different treatment compared to cigarettes, and I believe it's genuinely excellent that this concept of tobacco harm reduction has been acknowledged. On the other hand, a 20% gap appears insufficient. Naturally, this will have consequences, since we're gradually feeling its effects. And it's still too soon for me to estimate what the effect will be in the coming year. Naturally, some effect is going to be felt. Still, it won't throw off the basic direction we're on with IQOS or our earnings expansion. Even so, in our view, 20% simply won't cut it. We're therefore optimistic that at some future moment—though naturally it's premature to predict, since the incoming coalition hasn't taken shape yet, even as details are becoming clearer—there may be room, beginning at that 20% gap, for a roadmap to raise it gradually, and that's something that could happen. As for contagion, at present we aren't observing any. Looking at the most recent nation instead, what we're seeing is that they're now applying a more tailored approach for each one relative to CC. Typically, the gap versus Germany turns out to be considerably wider in most instances — exceeding 20%. Take Egypt as a single illustration: in the decision authorities recently made, they're plainly drawing a sharper distinction, and in my view that aligns much better with lowering exposure to toxicans. If you were after a rule to figure out what that gap ought to be, you'd land somewhere around 90 to 95%. That, perhaps, ought to serve as the guideline. It's encouraging that various nations, regulators, and authorities are now distinguishing between CC and < >, applying notably different tax rules to each.
Chris Growe
analystOkay. Thank you.
Emmanuel Babeau
executiveThank you.
Nicholas Rolli
executiveActually, I think Emmanuel has a few brief remarks.
Emmanuel Babeau
executiveCertainly. Thanks, Nick. Let me take just a second to finish up with a few quick remarks to close. To start, 2021 is shaping up to be an excellent year when it comes to IQOS expansion and how our business performs financially. We're seeing strong fundamentals, demand, and momentum for the IQOS brand continue; and finally, though certainly not least, even with short-term hurdles around device supply, we're still on course to hit the growth targets we set for 3 years, backed by a robust pipeline of innovation. So I really appreciate the time you've given us today, and we're eager to speak with you again before long.
Nicholas Rolli
executiveThanks a lot, Emmanuel. That brings the call to a close. Should any follow-up questions come up, feel free to reach out to the Investor Relations team. Thanks once more. Enjoy the rest of your day.
Emmanuel Babeau
executiveThank you. Talk to you soon. Bye-bye.
Operator
operatorThat wraps up this earnings call for Philip Morris International covering the third quarter of 2021. You're welcome to drop off at any point from here, and we'd put the range at 90% to 95%.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.